Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection?

J Am Coll Cardiol. 2003 Apr 2;41(7):1195-7. doi: 10.1016/s0735-1097(03)00087-1.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Aspirin / administration & dosage
  • Aspirin / pharmacology*
  • Clinical Trials as Topic
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / administration & dosage
  • Cyclooxygenase Inhibitors / pharmacology*
  • Disease Models, Animal
  • Humans
  • Ischemic Preconditioning, Myocardial*
  • Isoenzymes / drug effects*
  • Membrane Proteins
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / prevention & control
  • Myocardial Stunning / drug therapy
  • Myocardial Stunning / physiopathology*
  • Prostaglandin-Endoperoxide Synthases / drug effects*
  • Prostaglandin-Endoperoxide Synthases / physiology
  • Rabbits

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Aspirin